PFE: Sigvie-002 Trial Fails
Pfizer's Phase 3 Sigvie-002 trial of Sigvotatug Vedotin in advanced NSCLC did not meet primary endpoint of OS versus Docetaxel
Pfizer Says Phase 3 Sigvie‑002 Trial Of Sigvotatug Vedotin In Advanced NSCLC Did Not Meet Primary Endpoint Of OS Versus Docetaxel, Though Trends Favoured Antibody-Drug Conjugate In Patients With Only One Prior Line Of Therapy